CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Otsuka Pharmaceutical Co. Ltd. v. Hetero USA Inc.

1:15-cv-00822

Overview

Case Number 1:15-cv-00822
Filing Date 2015-09-15
Status Terminated
Termination Date 2015-12-14
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Hetero Labs Ltd. Unit V Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Hetero Labs Ltd. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Hetero USA Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Otsuka Pharmaceutical Co. Ltd. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 11 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (11): πŸ‡―πŸ‡΅ Japan πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5753677
Benzoheterocyclic compounds
Filed: 1995-06-07
Issued: 1998-05-19
Expired (Term Ended) +1808d PTA
Expires: 2020-05-19

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1808 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(18 total)
Pleading / Complaint

COMPLAINT filed against Hetero Labs Ltd., Hetero Labs Ltd. Unit V, Hetero USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1787962.) - filed by Otsuka Pharmaceutical Co. Ltd.. (Attachments: # 1 Exhibit A-Part 1, # 2 Exhibit A-Part 2, # 3 Exhibit A-Part 3, # 4 Civil Cover Sheet)(sec) (Entered: 09/16/2015)

Entry #1 • 2015-09-15
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sec) (Entered: 09/16/2015)

Entry #2 • 2015-09-15
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/31/2015. Date of Expiration of Patent: 5/19/2020.Thirty Month Stay Deadline: 2/28/2018. (sec) (Entered: 09/16/2015)

Entry #3 • 2015-09-15
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,753,677. (sec) (Entered: 09/16/2015)

Entry #4 • 2015-09-15
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Otsuka Pharmaceutical Co. Ltd. filed by Otsuka Pharmaceutical Co. Ltd.. (sec) (Entered: 09/16/2015)

Entry #5 • 2015-09-15
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc